Jacobs Levy Equity Management, Inc Precigen, Inc. Transaction History

Jacobs Levy Equity Management, Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$0.89 - $1.41 $280,155 - $443,841	-314,781 Reduced 45.77%	373,013 $499,000
Q3 2023 Nov 16, 2023	SELL	$1.08 - $1.85 $720,123 - $1.23 Million	-666,781 Reduced 49.22%	687,794 $976,000
Q2 2023 Aug 14, 2023	SELL	$0.96 - $1.4 $633,906 - $924,446	-660,319 Reduced 32.77%	1,354,575 $1.56 Million
Q1 2023 May 15, 2023	BUY	$0.88 - $2.19 $1.77 Million - $4.41 Million	2,014,894 New	2,014,894 $2.14 Million
Q3 2022 Nov 15, 2022	SELL	$1.41 - $2.79 $731,283 - $1.45 Million	-518,641 Reduced 68.87%	234,400 $497,000
Q2 2022 Aug 15, 2022	BUY	$1.15 - $2.53 $865,997 - $1.91 Million	753,041 New	753,041 $1.01 Million
Q3 2021 Nov 15, 2021	SELL	$4.99 - $6.55 $56,681 - $74,401	-11,359 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$6.24 - $8.22 $70,880 - $93,370	11,359 New	11,359 $74,000

148

162M

150K

29.5K

Ticker PGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 208,150,000
Market Cap $408M
Description
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorpora...

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.